Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn's disease: An open-label pilot study

Digestive Diseases and Sciences

Volumn 56, Issue 6, 2011, Pages 1806-1810

  James, Dustin G ^a   Seo, Da Hea ^a   Chen, Jiajing ^a   Vemulapalli, Caroline ^a   Stone, Christian D ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

Biologic therapies; Clinical trial; Crohn's disease; Efalizumab

Indexed keywords

EFALIZUMAB; IMMUNOMODULATING AGENT; MESALAZINE; NARCOTIC ANALGESIC AGENT; STEROID;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; COLONOSCOPY; CONSTIPATION; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX SCORE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; LEUKOCYTOSIS; MALE; MYALGIA; NAUSEA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; REMISSION; SCORING SYSTEM; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; VOMITING; WOUND HEALING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; YOUNG ADULT;

EID: 79959690272     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-010-1525-6     Document Type: Article

References (16)

1. Sandborn WJ. Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments. Rev Gastroenterol Disord. 2007;7:S23-S35.
2. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290:3133-3135.
3. Fischer A, Durandy A, Sterkers G, et al. Role of the LFA-1 molecule in cellular interactions required for antibody production in humans. J Immunol. 1986;136:3198-3203.
4. Dustin ML, Springer TA. Lymphocyte function-associated antigen (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol. 1988;107:321-331.
5. Werther WA, Gonzalez TN, O'Connor SJ, et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol. 1996;157:4986-4995. (Pubitemid 126449577)
6. Bernstein CN, Sargent M, Rector E. Alteration in expression of beta 2 integrins on lamina propria lymphocytes in ulcerative colitis and Crohn's disease. Clin Immunol. 2002;104:67-72. (Pubitemid 34856510)
7. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505-512. (Pubitemid 39311530)
8. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250. (Pubitemid 47080388)
9. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549. (Pubitemid 34621118)
10. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterol. 2007;132:52-65. (Pubitemid 46108762)
11. Guttman-Yassky E, Vugmeyster Y, Lowes MA, et al. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. J Invest Dermatol. 2008;128:1182-1191. (Pubitemid 351543222)
12. Leonardi C, Papp K, Gordon K, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005;52:425-433.
13. Food and Drug Administration (FDA). FDA approves updated labeling for psoriasis drug Raptiva. 2008. Available at: http://www.fda.gov/bbs/topics/NEWS/ 2008/NEW01905.html. Accessed 14 December 2010.
14. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369-374. (Pubitemid 41132341)
15. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353:362-368. (Pubitemid 41132340)
16. Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864-875.